⚠ Research and educational use only — not for human consumption. Nothing for sale, no dosing advice. PeptideCompare is non-profit and independent.
Compare free →
Suppliers 🛡 Quality & badges 📖 Encyclopedia 📰 Articles 🧪 Calculator
LONGEVITY TOPICS
⚡ NAD+ Precursors 🔑 Sirtuin Activators 🧹 Senolytics ♻️ Autophagy 🔋 Mitochondrial 🌡️ Hormesis
About FAQ Contact Policy
Home / Encyclopedia / GLP-1 & Weight / Tirzepatide vs Retatrutide
⚖️ GLP-1 & Weight

Tirzepatide vs Retatrutide

How do Tirzepatide and Retatrutide compare for GLP-1 & Weight research? Side-by-side evidence, molecular profile, EU legal status and COA-verified supplier prices — never dosing advice.

At a glance

Tirzepatide

⚖ GLP-1 & Weight
EVIDENCE BASEStrong
MECHANISM
GLP-1 · GIP dual
DEVELOPER
Eli Lilly
FDA STATUS
Approved (Mounjaro)
EU STATUS
EMA approved (Mounjaro)
RESEARCH STATUS
Research use only
WADA
Prohibited S0
MIN PURITY
≥98% HPLC
Molecular weight
4813.45 g/mol
CAS number
2023788-19-2
Route
Subcutaneous (weekly)
Half-life (t½)
≈5 days (~120 h)
Tmax
8–72 h
Bioavailability
≈80% (SC)
PRICE FROM
€37.9 · 7 EU vendors
View prices →

Retatrutide

⚖ GLP-1 & Weight
EVIDENCE BASEStrong
MECHANISM
GLP-1 · GIP · GCG
DEVELOPER
Eli Lilly
PHASE
Phase 3 (2024–)
CAS
2381090-02-2
EU STATUS
Research only
WADA
Prohibited S0
MIN PURITY
≥98% HPLC
Molecular weight
4731.4 g/mol
CAS number
2381090-02-2
Route
Subcutaneous (weekly)
Half-life (t½)
≈6 days (~144 h)
Tmax
12–72 h
PRICE FROM
€44.49 · 15 EU vendors
View prices →

Which fits which research target?

Both Tirzepatide and Retatrutide sit within GLP-1 & Weight research but are studied for different primary signals. Neither is an approved medicine — compare the evidence, not marketing claims.

PRIMARY RESEARCH SIGNAL
Tirzepatide
Weight reduction
Retatrutide
Weight reduction
Neither Tirzepatide nor Retatrutide is an approved medicine. All comparisons here are research observations, not usage, dosing or efficacy recommendations.

What the research shows

Tirzepatide

EVIDENCE SUMMARY
STRONG
Weight reduction — SURMOUNT-1 trial: up to 22.5% body weight reduction at 72 weeks. FDA approved for obesity (Zepbound) in 2023.
STRONG
Glycemic control — SURPASS trial series: superior HbA1c reduction vs semaglutide in head-to-head. FDA approved for T2D (Mounjaro) in 2022.
STRONG
Cardiovascular outcomes — SURMOUNT-MMO cardiovascular outcomes trial data published 2025. Significant CV risk reduction.

Retatrutide

EVIDENCE SUMMARY
STRONG
Weight reduction — Phase 2 NEJM-published trial: up to 24.2% body weight reduction at 48 weeks at highest dose. Dose-dependent. Superiority to semaglutide and tirzepatide in head-to-head observations.
STRONG
Glycemic control — Significant HbA1c reductions across all dose groups in Phase 2. GLP-1 + GIP synergy well-established from tirzepatide data.
MODERATE
Metabolic markers — Improvements in lipid profiles, liver fat, and insulin sensitivity observed in Phase 2. Glucagon component may improve hepatic outcomes.
PHASE 3 PENDING
Long-term safety, cardiovascular outcomes — Phase 3 TRIUMPH trials ongoing as of 2026. Long-term safety profile not yet established to the same degree as approved GLP-1 drugs.

Compare prices across EU suppliers

Compare Tirzepatide across EU suppliers

7 EU vendors · COA · from €37.9

View prices →

Compare Retatrutide across EU suppliers

15 EU vendors · COA · from €44.49

View prices →

Frequently asked questions

Is Tirzepatide or Retatrutide better?

Neither is an approved medicine, and “better” depends on the research target. Tirzepatide is most associated with Weight reduction, while Retatrutide is studied for Weight reduction. Compare the evidence tiers and COA-verified EU pricing above rather than assuming one is superior. This is not a usage recommendation.

Why compare Tirzepatide and Retatrutide?

Both are studied within GLP-1 & Weight research through different mechanisms, so researchers often weigh them against each other. This page sets their evidence, molecular profile, EU legal status and supplier pricing side by side.

Which is cheaper in the EU, Tirzepatide or Retatrutide?

Prices vary by supplier, vial size and COA status. Tirzepatide is listed from €37.9 across 7 COA-verified EU vendors; Retatrutide from €44.49 across 15. Open the price pages above to compare current listings — nobody pays us for placement.

Read the full guides

PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
What does COA Verified mean? Most tested supplier? Is this legal here?
Navigation assistant · no medical advice